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A new series of some novel acetazolamide cyclocondensed 1,2,3,4-tetrahydropyrimidines
was prepared by reacting of N-{[5-(acetylamino)-1,3,4-thiadiazol-2-yl]sulfonyl}-3-
oxobutanamide with urea/thiourea and appropriate aldehyde in the presence of catalytic
amount of laboratory made p-toluenesulfonic acid as an efficient catalyst. Confirmation of
the chemical structure of the synthesized compounds (12aen) was substantiated by TLC,
different spectral data IR, 1H NMR, Mass spectra and elemental analysis were done. The
synthesized compounds were evaluated for in-vitro antimicrobial and cytotoxicity against
Bacillus subtilis, Escherichia coli and Vero cells. The titled compounds exhibited weak,
moderate, or high in-vitro antimicrobial and cytotoxicity. Compounds 12c, 12d, 12g and
12h, exhibited potential antimicrobial and in-vitro cytotoxicity.
Copyright 2014, Beni-Suef University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
The advent of microwave assisted technology in organic
chemistry dates back to the mid 1980s and since the 1990sResearch, Department of M
i-Suef University
sevier
ity. Production and hostthere has been a significant increase in the number of publi-
cations on Microwave Assisted Organic Reactions (MAOS) due
to increased benefits associated with the process (Langa et al.,
1997; Strauss and Trainor, 1995; Wathey et al., 2002). The
promotion of microwave assisted reactions in organicedicinal Chemistry, Sunrise University, Alwar, Rajasthan -301030,
ing by Elsevier B.V. All rights reserved.
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energy spent making it a sustainable process and is widely
heralded as “green chemistry” measures whose applications
are promoted today to minimize the use of non renewable
resources as well as polluting solvent, to reduce generation of
secondary products which are often toxic and to reduce the
emission of harmful gases (Prasad et al., 2012; Tucker, 2010;
Wang et al., 2011). Microwave assisted reactions in organic
chemistry achieve the facilitation of faster reactions under
bulk conditions as well as promoting reduction of reaction
time (Erdmenger et al., 2010).
Pyrimidine derivatives comprise a diverse and interesting
group of drugs is extremely important for their biological activ-
ities. Dihydropyrimidine and their derivatives have attracted
increasing interest owing to their therapeutic and pharmaceu-
tical properties, such as antiviral, antitubercular (Desai et al.,
2001; Singh et al., 2011; Prashantha Kumar et al., 2008), antimi-
crobialagent (Baldevetal., 2012;Bhuiyanetal., 2006;Shettyetal.,
2009; Sharma et al., 2004; Vasudeva Rao et al., 2012; El-Sayed
et al., 2012) antagonists of the human adenosine A2A receptor
(Gillespie et al., 2008), cyclooxygenase-2 inhibitory activity
(Orjalesetal., 2008;Falcaoetal., 2006), tyrosinekinase inhibitors,
antiamoebic activity (Gangjee et al., 2010; Parveen et al., 2010)
and cytotoxicity (Xie et al., 2009; Saritha Jyostna and Achaiah,
2010; Vasudeva Rao et al., 2012). The discovery during the
1930s that a dihydropyridine (dihydronicotinamide derivative,
NADH), “hydrogen-transferring coenzyme” consequently
became important in biological system, has generated
numerous studies on the biochemical properties of dihy-
dropyridines and their bioisosteres dihydropyrimidines. The
search for more suitable preparation of dihydropyrimidinones
continues today.
The chemical structure of acetazolamide provides a most
valuablemolecular template for the development of agents able
to interact with a wide variety of biological activities
(Karthikeyan et al., 2013; Kushwaha et al., 2012). Tetrahy-
dropyrimidines are structurally similar to dihydropyrimidines.
Hence, it was thought worthwhile to synthesize new congeners
by incorporating acetazolamide with 1,2,3,4-tetrahydropyrimi
dinones moieties in a single molecular frame work and to eval-
uate their antimicrobial and cytotoxicity.2. Experimental
2.1. Materials and methods
All chemicals were supplied by E.Merck (Germany) and SD fine
chemicals (India). Melting points were determined by open
tube capillary method and are uncorrected. Purity of the
compounds was checked on thin layer chromatography (TLC)
plates (silica gel G) in the solvent system ethanol, chloroform,
ethylacetate (6:3:1); the spots were located under iodine va-
pors or UV light. IR spectrums were obtained on a Per-
kineElmer 1720 FT-IR spectrometer (KBr Pellets). 1H NMR
spectra were recorded or a Bruker DRX-300 (300 MHz FT-NMR)
spectrometer using DMSO-d6 as solvent and TMS as internal
standard. Mass spectra were obtained using Shimadzu LCMS
2010A under ESI ionization technique.2.1.1. Preparation of N-{[5-(acetylamino)-1,3,4-thiadiazol-2-
yl]sulfonyl}-3-oxobutanamide (3)
Acetazolamide 1 (0.01 M) and ethylacetoacetate 2 (0.01 M)
were mixed in presence 10 ml of glacial acetic acid and
refluxed for approximately 4.5 h. The colorless liquid formed
was then heated on awater bath to remove the alcohol formed
during the reaction. After allowing the reaction mixture to
cool, crude crystals were obtained. Purificationwas performed
by stirring crude crystals with cold diethyl ether for approxi-
mately 20 min using a mechanical stirrer. Allowing it to stand
for 15 min, followed by filtration, resulted in the third com-
pound in a pure form of N-{[5-(acetylamino)-1,3,4-thiadiazol-
2-yl]sulfonyl}-3-oxobutanamide 3.
2.2. General procedure
2.2.1. Preparation of 1,2,3,4-tetrahydropyrimidines by
microwave irradiation method(12aen)
The mixture of N-{[5-(acetylamino)-1,3,4-thiadiazol-2-yl]sul-
fonyl}-3-oxobutanamide (0.005 M), urea/thiourea (0.0075 M),
and appropriate aldehyde (0.005 M) with catalytic amount of
p-toluenesulfonic acid in 10 ml of ethanol was subjected to
microwave irradiation (300 W) for 10 min at the interval of
10 s. The reactions were monitored through TLC using 25
percent ethylacetate in pet ether as solvent system. After the
reaction was complete, the reaction mixture was cooled in a
refrigerator and filtered. The precipitate obtained was
washed thoroughly with water to remove unreacted urea/
thiourea and dried. The crude solid product was recrystal-
lized with ethanol to give the pure compounds (12aen).
2.3. Analytical data
2.3.1. N-{[5-(acetylamino)-1,3,4-thiadiazol-2-yl]sulfonyl}-3-
oxobutanamide (3)
Light-bluish crystalline solid, M.P.: 188e190 C; Yield: 74%; IR
(KBr, cm1): 3332 (NeH), 2864 (AliCeH), 1734 (C]O, ketone),
1686 (C]O, amide), 1542 (C]C), 1326 (CeN); 1H NMR (DMSO-
d6) d: 2.09 (s, 3H, CH3), 3.42 (s, 2H, CH2), 9.44 (s, 1H, NH), 9.68 (s,
1H, NH); calculated for C8H10N4O5S2: C, 31.37; H, 3.29; N, 18.29;
found C, 31.42; H, 3.25; N, 18.35.
2.3.2. N-{[5-(acetylamino)-1,3,4-thiadiazol-2-yl]sulfonyl}-4-
(3-chlorophenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-
5-carboxamide (12a)
Dark-brownish solid, M.P.: 258e260 C; Yield: 69%; IR (KBr,
cm1): 3258 (NeH), 3146 (ArCeH), 2932 (AliCeH), 1663 (C]O,
amide), 1571 (C]C), 1237 (OeC); 1H NMR (DMSO-d6) d: 2.07 (s,
3H, CH3), 3.63 (s, 3H, CH3), 5.39 (s, 1H, CH), 7.33 (d, 2H, ArH), 7.84
(d, 2H, ArH), 8.88 (s, 1H, NH), 8.94 (s, 1H, NH), 9.62 (s, 1H, NH),
10.08 (s, 1H, NH); MS (m/z): (M þ 1) calculated 472.00; Found
472.05; Calculated for C16H15ClN6O5S2: C, 40.81; H, 3.21; N,
17.85; found C, 40.86; H, 3.19; N, 17.88.
2.3.3. N-{[5-(acetylamino)-1,3,4-thiadiazol-2-yl]sulfonyl}-4-
(3-chlorophenyl)-6-methyl-2-thioxo-1,2,3,4-
tetrahydropyrimidine-5-carboxamide (12b)
Light-ash-colored solid, M.P.: 284e287 C; Yield: 76%; IR (KBr,
cm1): 3246 (NeH), 3146 (ArCeH), 2938 (AliCeH), 1628 (C]O,
amide), 1557 (C]C), 1884 (C]S), 1176 (OeC); 1H NMR (DMSO-
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2H, ArH), 7.18 (d, 2H, ArH), 9.16 (s, 1H, NH), 9.47 (s, 1H, NH), 9.78
(s, 1H, NH), 10.14 (s, 1H, NH); MS (m/z): (M þ 1) calculated
488.00; found 488.06. Calculated for C16H15ClN6O4S3: C, 39.46;
H, 3.10; N, 17.26; found C, 39.50; H, 3.07; N, 17.30.
2.3.4. N-{[5-(acetylamino)-1,3,4-thiadiazol-2-yl]sulfonyl}-4-
(4-chlorophenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-
5-carboxamide (12c)
Light-greenish-colored solid, M.P.: 292e295 C; Yield: 81%; IR
(KBr, cm1): 3316 (NeH), 3232 (ArCeH), 2944 (AliCeH), 1678
(C]O, amide), 1591 (C]C), 1342 (OeC); 1H NMR (DMSO-d6) d:
2.04 (s, 3H, CH3), 3.72 (s, 3H, CH3), 5.47 (s, 1H, CH), 7.21 (d, 2H,
ArH), 7.74 (d, 2H, ArH), 8.89 (s, 1H, NH), 9.31 (s, 1H, NH), 9.79 (s,
1H, NH), 9.94 (s, 1H, NH); MS (m/z): (M þ 1) calculated 472.00;
found 471.96; Calculated for C16H15ClN6O5S2: C, 40.82; H, 3.21;
N, 17.85; found C, 40.79; H, 3.23; N, 17.82.
2.3.5. N-{[5-(acetylamino)-1,3,4-thiadiazol-2-yl]sulfonyl}-4-
(4-chlorophenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimi
dine-5-carboxamide (12d)
Ash-colored solid, M.P.: 304e307 C; Yield: 84%; IR (KBr, cm1):
3272 (NeH), 3137 (ArCeH), 2968 (AliCeH), 1647 (C]O, amide),
1568 (C]C), 1872 (C]S), 1218 (OeC); 1H NMR (DMSO-d6) d: 2.07
(s, 3H, CH3), 3.50 (s, 3H, CH3), 5.52 (s, 1H, CH), 7.31 (d, 2H, ArH),
7.84 (d, 2H, ArH), 8.88 (s, 1H, NH), 9.32 (s, 1H, NH), 9.54 (s, 1H,
NH), 10.06 (s, 1H, NH); MS (m/z): (M þ 1) calculated 488.00;
found 487.98; Calculated for C16H15ClN6O4S3: C, 39.46; H, 3.10;
N, 17.26; found C, 39.44; H, 3.12; N, 17.29.
2.3.6. N-{[5-(acetylamino)-1,3,4-thiadiazol-2-yl]sulfonyl}-6-
methyl-4-(3-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-
5-carboxamide (12e)
Light-yellowishsolid,M.P.: 321e323 C;Yield:74%; IR (KBr, cm1):
3378 (NeH), 3146 (ArCeH), 2958 (AliCeH), 1648 (C]Oamide),1545
(C]C), 1268 (CeO); 1HNMR (DMSO-d6) d: 2.03 (s, 3H, CH3), 3.65 (s,
3H, CH3), 5.71 (s, 1H, CH), 7.26e7.36 (t, 3H, ArH), 8.79 (s, 1H, NH),
9.24 (s, 1H,NH), 9.56 (s, 1H,NH), 10.08 (s, 1H,NH);MS (m/z): (Mþ 1)
calculated 482.00; found 482.06; Calculated for C16H15N7O7S2: C,
39.91; H, 3.14; N, 20.36; found C, 39.87; H, 3.09; N, 20.40.
2.3.7. N-{[5-(acetylamino)-1,3,4-thiadiazol-2-yl]sulfonyl}-6-
methyl-4-(3-nitrophenyl)-2-thioxo-1,2,3,4-tetrahydropyrimi
dine-5-carboxamide (12f)
Ash-colored solid, M.P.: 308e3011 C; Yield: 80%; IR (KBr,
cm1): 3257 (NeH), 3156 (ArCeH), 2966 (AliCeH), 1648 (C]O,
amide), 1588 (C]C), 1846 (C]S), 1177 (OeC); 1H NMR (DMSO-
d6) d: 2.07 (s, 3H, CH3), 3.71 (s, 3H, CH3), 5.58 (s, 1H, CH), 6.72 (d,
2H, ArH), 7.66 (d, 2H, ArH), 8.74 (s, 1H, NH), 9.24 (s, 1H, NH), 9.47
(s, 1H, NH), 10.01 (s, 1H, NH); MS (m/z): (M þ 1) calculated
498.00; found 498.04; Calculated for C16H15N7O6S3: C, 38.63; H,
3.04; N, 19.71; found C, 38.59; H, 3.01; N, 19.7.
2.3.8. N-{[5-(acetylamino)-1,3,4-thiadiazol-2-yl]sulfonyl}-4-
(4-fluorophenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-
5-carboxamide (12g)
Light-bluish-colored solid, M.P.: 342e345 C; Yield: 85%; IR
(KBr, cm1): 3247 (NeH), 3182 (ArCeH), 2938 (AliCeH), 1647
(C]O, amide), 1544 (C]C), 1182 (OeC); 1H NMR (DMSO-d6) d:
2.02 (s, 3H, CH3), 3.69 (s, 3H, CH3), 5.51 (s, 1H, CH), 7.34 (d, 2H,ArH), 7.86 (d, 2H, ArH), 8.88 (s, 1H, NH), 9.47 (s, 1H, NH), 9.94 (s,
1H, NH), 10.06 (s, 1H, NH); MS (m/z): (M þ 1) calculated 455.00;
found 455.04; Calculated for C16H15FN6O5S2: C, 42.29; H, 3.33; N,
18.49; found C, 42.27; H, 3.37; N, 18.47.
2.3.9. N-{[5-(acetylamino)-1,3,4-thiadiazol-2-yl]sulfonyl}-4-
(4-fluorophenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimi
dine-5-carboxamide (12h)
Light-greenish solid, M.P.: 351e353 C; Yield: 83%; IR (KBr,
cm1): 3238 (NeH), 3154 (ArCeH), 2974 (AliCeH), 1666 (C]O,
amide), 1573 (C]C), 1836 (C]S), 1153 (OeC); 1H NMR (DMSO-
d6) d: 2.09 (s, 3H, CH3), 3.78 (s, 3H, CH3), 5.42 (s, 1H, CH), 7.46 (d,
2H, ArH), 7.84 (d, 2H, ArH), 8.89 (s, 1H, NH), 9.34 (s, 1H, NH), 9.88
(s, 1H, NH), 10.06 (s, 1H, NH); MS (m/z): (M þ 1) calculated
471.00; found 470.96; Calculated for C16H15FN6O4S3: C, 40.84; H,
3.21; N, 17.86; found C, 40.81; H, 3.25; N, 17.81.
2.3.10. N-{[5-(acetylamino)-1,3,4-thiadiazol-2-yl]sulfonyl}-6-
methyl-4-(2-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-
5-carboxamide (12i)
Ash-colored solid, M.P.: 284e287 C; Yield: 70%; IR (KBr, cm1):
3238 (NeH), 3148 (ArCeH), 2957 (AliCeH), 1648 (C]O, amide),
1554 (C]C), 1128 (OeC); 1H NMR (DMSO-d6) d: 2.04 (s, 3H, CH3),
3.71 (s, 3H, CH3), 5.46 (s, 1H, CH), 7.38 (d, 2H, ArH), 7.92 (d, 2H,
ArH), 8.78 (s, 1H, NH), 9.31 (s, 1H, NH), 9.72 (s, 1H, NH), 9.72 (s,
1H, NH); MS (m/z): (M þ 1) calculated 482.00; found 482.05;
Calculated for C16H15N7O7S2: C, 39.91; H, 3.14; N, 20.36; found
C, 39.95; H, 3.10; N, 20.31.
2.3.11. N-{[5-(acetylamino)-1,3,4-thiadiazol-2-yl]sulfonyl}-6-
methyl-4-(2-nitrophenyl)-2-thioxo-1,2,3,4-tetrahydropyrimi
dine-5-carboxamide (12j)
Light-yellowish solid, M.P.: 296e299 C; Yield: 73%; IR (KBr,
cm1): 3238 (NeH), 3173 (ArCeH), 2942 (AliCeH), 1674 (C]O,
amide), 1584 (C]C), 1847 (C]S), 1166 (OeC); 1H NMR (DMSO-
d6) d: 2.04 (s, 3H, CH3), 3.59 (s, 3H, CH3), 5.57 (s, 1H, CH), 7.39 (d,
2H, ArH), 7.84 (d, 2H, ArH), 8.84 (s, 1H, NH), 9.35 (s, 1H, NH), 9.92
(s, 1H, NH), 10.13 (s, 1H, NH); MS (m/z): (M þ 1) calculated
498.00; found 497.94; Calculated for C16H15N7O6S3: C, 38.63; H,
3.04; N, 19.71; found C, 38.59; H, 3.08; N, 19.66.
2.3.12. N-{[5-(acetylamino)-1,3,4-thiadiazol-2-yl]sulfonyl}-4-
(2-chlorophenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-
5-carboxamide (12k)
Light-yellowish solid, M.P.: 318e321 C; Yield: 72%; IR (KBr,
cm1): 3246 (NeH), 3174 (ArCeH), 2947 (AliCeH), 1674 (C]O,
amide), 1572 (C]C), 1138 (OeC); 1H NMR (DMSO-d6) d: 2.05 (s,
3H, CH3), 3.68 (s, 3H, CH3), 5.43 (s, 1H, CH), 7.46 (d, 2H, ArH), 7.87
(d, 2H, ArH), 8.74 (s, 1H, NH), 9.47 (s, 1H, NH), 9.89 (s, 1H, NH),
10.08 (s, 1H, NH); MS (m/z): (M þ 1) calculated 472.00; found
471.98; Calculated for C16H15ClN6O5S2: C, 40.81; H, 3.21; N,
17.85; found C, 40.77; H, 3.24; N, 17.89.
2.3.13. N-{[5-(acetylamino)-1,3,4-thiadiazol-2-yl]sulfonyl}-4-
(2-chlorophenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimi
dine-5-carboxamide (12l)
Light-bluish-colored solid, M.P.: 335e337 C; Yield: 77%; IR
(KBr, cm1): 3247 (NeH), 3133 (ArCeH), 2958 (AliCeH), 1683
(C]O, amide), 1528 (C]C), 1846 (C]S), 1158 (OeC); 1H NMR
(DMSO-d6) d: 2.04 (s, 3H, CH3), 3.75 (s, 3H, CH3), 5.53 (s, 1H, CH),
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NH), 9.89 (s, 1H, NH), 10.06 (s, 1H, NH); MS (m/z): (M þ 1)
calculated 488.0; found 488.06; Calculated for C16H15ClN6O4S3:
C, 39.46; H, 3.10; N, 17.26; found C, 39.41; H, 3.07; N, 17.30.
2.3.14. N-{[5-(acetylamino)-1,3,4-thiadiazol-2-yl]sulfonyl}-6-
methyl-2-oxo-4-(pyridin-4-yl)-1,2,3,4-tetrahydropyrimidine-5-
carboxamide (12m)
Ash-colored solid, M.P.: 289e291 C; Yield: 69%; IR (KBr, cm1):
3238 (NeH), 3166 (ArCeH), 2951 (AliCeH), 1664 (C]O, amide),
1592 (C]C), 1169 (OeC); 1H NMR (DMSO-d6) d: 2.02 (s, 3H, CH3),
3.82 (s, 3H, CH3), 5.43 (s, 1H, CH), 7.29 (d, 2H, ArH), 7.82 (d, 2H,
ArH), 8.88 (s, 1H, NH), 9.39 (s, 1H, NH), 9.92 (s, 1H, NH), 10.07 (s,
1H, NH); MS (m/z): (M þ 1) calculated 438.00; found 438.04;
Calculated for C15H15N7O5S2: C, 41.18; H, 3.46; N, 22.41; found
C, 41.22; H, 3.39; N, 22.47.
2.3.15. N-{[5-(acetylamino)-1,3,4-thiadiazol-2-yl]sulfonyl}-6-
methyl-4-(pyridin-4-yl)-2-thioxo-1,2,3,4-tetrahydropyrimidine-
5-carboxamide (12n)
Light-bluish-colored solid, M.P.: 356e358 C; Yield 73%; IR (KBr,
cm1): 3253 (NeH), 3148 (ArCeH), 2968 (AliCeH), 1654 (C]O,Growth inhibition % ¼ 100 ½sample absorbance=control absorbance  100amide), 1538 (C]C), 1824 (C]S), 1136 (OeC); 1H NMR (DMSO-
d6) d: 2.06 (s, 3H, CH3), 3.73 (s, 3H, CH3), 5.43 (s, 1H, CH), 7.38 (d,
2H, ArH), 7.88 (d, 2H, ArH), 8.93 (s, 1H, NH), 9.39 (s, 1H, NH), 9.92
(s, 1H, NH), 10.08 (s, 1H, NH); MS (m/z): (M þ 1) calculated
454.00; found 453.95; Calculated for C15H15N7O4S3: C, 39.73; H,
3.33; N, 21.62; found C, 39.69; H, 3.38; N, 21.66.
2.4. Antimicrobial activity
The in-vitro antibacterial activities were tested against Gram-
positive bacteria Bacillus subtilis and Gram-negative bacteria
Escherichia coli by standard serial dilutionmethod using a stock
solution of 100 mg/ml concentrations (Vasudeva Rao et al.,
2012; Zhu et al., 2009). Double strength nutrient broth was
used as culture media and dimethyl sulphoxide (DMSO) was
used as solvent control. The stock solutions of the test com-
pounds were serially diluted in test tubes containing 1 ml of
sterile medium to get the different concentrations and then
inoculated with 100 ml of suspension of respective microor-
ganism in sterile saline. Norfloxacin (Nfn) was used as stan-
dard drug. The inoculated test tubes were incubated at
37  1 C for 24 h.
2.5. In-vitro cytotoxicity
Short-term in-vitro cytotoxicity assay was performed using
Vero cells according to the standard procedure (Prashantha
Kumar et al., 2010). SRB is a bright-pink aminoxanthene dye
with two sulfonic groups. Under mild acidic conditions, SRB
binds to protein basic amino acid residues in trichloroaceticacid fixed cells to provide a sensitive index of cellular pro-
tein content that is linear over a cell density range of at least
two orders of magnitude. After incubation, the solutions in
the wells were flicked off and 100 ml of different concen-
trations (2e500 mg) of compounds were added to the cells
and incubated at 37 C for 3 days in 5% CO2 atmosphere. The
microscopic examinations were performed and observa-
tions were recorded every 24 h. After, 72 h, 50% trichloro-
acetic acid (25 ml) was added to each well and the plates
were incubated for 1 h at 4 C. The supernatant was then
removed, and the cells were washed with water, air-dried,
and stained, each well with SRB for 30 min. The unbound
dye was removed by washing with 1% acetic acid and the
plates were air-dried. Tris base (10 mM, 100 ml) was added to
wells to solubilize the dye. The plates were vigorously
shaken for 5 min, and the absorbance was measured using
microtiter plate reader at 540 nm. The mean absorbance of
triplicate was recorded. Mean absorbance taken from cells
grown in the absence of the test compound was taken as
100% cell survival (control). Tamoxifen (Tfn) was used as
standard drug. The percentage growth inhibition was
calculated using the following formula:3. Results and discussion
A series of 14 novel acetazolamide cyclocondensed 1,2,3,4-
tetrahydropyrimidines of biological interest were synthe-
sized and evaluated for antimicrobial and cytotoxicity, all the
compounds were characterized by IR, 1H NMR, MS and
elemental analysis for their structures.3.1. Chemistry
Synthesis of 1,4-dihydropyrimidines by adopting Biginelli
synthetic protocol (Prashantha Kumar et al., 2009) involving
one potmulticomponent reactionwas performed by following
steps as outlined in Fig. 1. In the first step, ethylacetoacetate 2
and acetazolamide 1 in presence 10 ml of glacial acetic acid
reacted under neat conditions resulting in the formation of N-
{[5-(acetylamino)-1,3,4-thiadiazol-2-yl]sulfonyl}-3-oxobutana
mide 3 with the yield of 74 percent. The N-{[5-(acetylamino)-
1,3,4-thiadiazol-2-yl]sulfonyl}-3-oxobutanamide was further
taken for the Biginelli condensation reaction by reacting it
with urea/thiourea and appropriate aldehyde in the presence
of catalytic amount of p-toluenesulfonic acid. The advantages
of the catalyst were better yields and do not require dry
solvents.
The first step in themechanismof theBiginelli reaction is the
acid-catalyzed condensation of the ureawith the aldehyde. This
reactionbeginswithprotonationof the aldehydeby theacidand
is followed by attack of the amine from urea. Proton transfer
stepsthenresult inaprotonatedalcoholwhich leavesaswaterto
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Fig. 2 e General mechanism of Biginelli tetrahydropyrimidines.
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Fig. 1 e Synthesis of compounds (12ae12n). R for compounds: 12a: (3-chlorophenyl); 12b: (3-chlorophenyl); 12c: (4-
chlorophenyl); 12d: (4-chlorophenyl); 12e:(3-nitrophenyl); 12f: (3-nitrophenyl); 12g: (4-flurophenyl); 12h: (4-flurophenyl); 12i:
(2-nitorophenyl); 12j: (2-nitorophenyl); 12k: (2-chlorophenyl); 12l: (2-chlorophenyl); 12m: (4-pyridyl); 12n: (4-pyridyl).
Reagents and conditions: (a) reflux 4.5 h, CH3COOH; (b) C2H5OH, p-toluenesulfonic acid, and microwave irradiation (300 W)
for 10 min.
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Fig. 3 e In-vitro antimicrobial activity of synthesized
compounds and norfloxacin (Nfn).
b e n i - s u e f u n i v e r s i t y j o u r n a l o f b a s i c a n d a p p l i e d s c i e n c e s 3 ( 2 0 1 4 ) 2 4e3 1 29form an N-acyliminium ion intermediate. (Oliver Kappe, 1997),
subsequently enol form of the b-Keto ester attacks the N-acyli-
minum ion to generate an open chain Ureide which readily cy-
clizes to a tetrahydropyrimidines (Fig. 2). The reaction times
were found to be 10 min. The IR spectra of compounds 12a-12n
showed strong absorption bands for amide group
(1628e1683 cm1), aromatic CeH stretching (3137e3232 cm1)
and aromatic C]C stretching (1528e1592 cm1). 1H NMR spec-
trum of compounds 12ae12n showed a methyl group protons
singlet at (2.02e3.82 ppm), CH-R protons singlet at
(5.26e5.71 ppm), aromatic protons doublet at (6.48e7.92 ppm)
and amine protons singlet at (8.74e10.14 ppm). The elemental
analysis results were within 0.6% of the theoretical values.
Totally, fourteencompounds12aen, various substituted 1,2,3,4-
tetrahydropyrimidines, were synthesizedwith the yield rangingTable 1 e Synthesized 1,2,3,4-tetrahydropyrimidines: in-vitro
tetrahydropyrimidines.
S
O
S
NN
NH
CH3
O
S. no. Compound R X B
MIC
1 12a 3-Chlorophenyl O
2 12b 3-Chlorophenyl S
3 12c 4-Chlorophenyl O
4 12d 4-Chlorophenyl S
5 12e 3-Nitrophenyl O
6 12f 3-Nitrophenyl S
7 12g 4-Flurophenyl O
8 12h 4-Flurophenyl S
9 12i 2-Nitorophenyl O
10 12j 2-Nitorophenyl S
11 12k 2-Chlorophenyl O
12 12l 2-Chlorophenyl S
13 12m 4-Pyridyl O
14 12n 4-Pyridyl S
15 Norfloxacin Standard e
16 Tamoxifen Standard efrom69 to 85percent. These conditions enable thismethod to be
applicable for the synthesis of 1,2,3,4-tetrahydropyrimidines
based heterocyclic compounds. The present protocol best de-
scribes the synthesis of 1,2,3,4-tetrahydropyrimidines. All the
reported 1,2,3,4-tetrahydropyrimidines compounds were found
to be novel and not reported elsewhere.
3.2. Antimicrobial activity
The synthesized compounds were subjected to in-vitro anti-
microbial activity against Gram-positive bacteria B. subtilis,
Gram-negative bacteria E. coli. The motive is to check the
antimicrobial activity for the synthesized compounds. Anti-
microbial activity of the synthesized compounds is shown in
(Fig. 3 and Table 1). The data listed in (Fig. 3 and Table 1) clearly
showed that most of the designed compounds exhibited good
to moderate inhibitory activities toward the Gram-positive
bacteria B. subtilis, Gram-negative bacteria E. coli. All the
1,2,3,4-tetrahydropyrimidines were potent antimicrobial
agent, with an MIC value ranging from micromolar to sub-
micromolar. Especially, compounds 12c, 12d, 12g and 12h
showed the best antimicrobial activity (Fig. 3 and Table 1).
3.3. In-vitro cytotoxicity
The synthesized compounds were subjected to in-vitro cyto-
toxicity assay against Vero cells. The assay was performed by
the sulforhodamine B (SRB) method (Prashantha Kumar et al.,
2009). Almost all of the titled compounds exhibited weak,
moderate, or high cytotoxicity. Compounds, 12c, 12d, 12g andantimicrobial and cytotoxicity. General structure of 1,2,3,4-
NH
N
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CH3 X
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. subtilis
(mmol/ml)
E. coli
MIC (mmol/ml)
CTC50
(mg/ml) on Vero cells
0.0164 0.0248 27.75
0.0158 0.0254 22.50
0.0129 0.0134 12.5
0.0125 0.0131 10
0.0489 0.0277 38
0.0436 0.0219 31
0.0118 0.0128 10
0.0114 0.0121 08
0.1653 0.0321 68
0.1762 0.0278 74
0.1564 0.0267 120
0.1782 0.0228 116
0.0834 0.0198 20
0.0786 0.0192 16
0.0128 0.0132 e
e e 12
Fig. 4 e In-vitro cytotoxicity of synthesized compounds
and tamoxifen (Tfn).
b e n i - s u e f un i v e r s i t y j o u rn a l o f b a s i c a n d a p p l i e d s c i e n c e s 3 ( 2 0 1 4 ) 2 4e3 13012h exhibited significant cytotoxic activity with lesser CTC50
value (Fig. 4 and Table 1). The goal of the cytotoxicity screening
in the discovery of new antibacterial is not necessarily to
identify the best compound but rather to identify active hits
thathaveattributes thatare goodenough tobecomesuccessful
drugs after chemo type optimization (Peternel et al., 2009). In
other words, the main goal of the initial cytotoxicity screen is
compound classification and not investigation of the mecha-
nism of cytotoxicity. In general, cytotoxicity screens are
applied only for compounds that pass the desired antibacterial
activity criteria in the first-line antibacterial efficacy screening
campaign. Byusing suchanapproach, seemingly little concern
is given tomissing important leads thatmay be less potent but
safe. Therefore, it is paramount to perform antibacterial effi-
cacy and cytotoxicity assays in parallel, resulting in instant
determination of the CTC50/MIC ratio and thereby of safety
margins.
Analyzing the activities of the synthesized compounds, the
following structure activity relationships (SARs) were ob-
tained. The fifth position of 1,2,3,4-tetrahydropyrimidines
contain N-{[5-(acetylamino)-1,3,4-thiadiazol-2-yl]sulfonyl}-3-
oxobutanamide group contributed toward antimicrobial and
cytotoxicity activity and fourth positions of 1,2,3,4-
tetrahydropyrimidines contain substituted phenyl and het-
ero aromatic ring responsible antimicrobial and cytotoxicity
potency (Prashantha Kumar et al., 2009). Substituted atom or
group of atommust be strong electron withdrawing nature for
potent activity because it decreases electron density in the
ring due to inductive effect. Fluoride and chloride substitution
at fourth position of phenyl ring showed potent antimicrobial
and cytotoxicity because of strong electron withdrawing na-
ture due to inductive effect. Substitution of chloro group at
third position of phenyl ring showed potent action when
compare with nitro atom. Introduction of heterocyclic ring at
forth position it showed moderate antimicrobial and cyto-
toxicity. The second position sulfur substituted derivatives
most potent when compare with oxygen atom. Among the
compounds reported here in, compounds (12c, 12d, 12g and
12h) is arguably the most potent when compare with current
therapeutic agent norfloxacin and tamoxifen because fluoride
and chloride substituted phenyl ring present at 4th position of
1,2,3,4-tetrahydropyrimidines it enhances the antimicrobial
and cytotoxicity (Figs. 3 and 4 and Table 1).4. Conclusion
A series of novel 1,2,3,4-tetrahydropyrimidines of biological
interest were synthesized and analyzed for their structures.
The libraries of compounds were prepared by using laboratory
made p-toluenesulfonic acid as an efficient catalyst when
compare with Lewis acid. The importance of substitutions at
the fourth positions of 1,2,3,4-tetrahydropyrimidines was
studied toward the antimicrobial and cytotoxicity. The anti-
microbial and cytotoxicity data revealed that the all synthe-
sized compounds proved to be active against the test
organism B. subtilis, E. coli, and Vero cells. Almost all of the
titled compounds exhibited weak, moderate, or high antimi-
crobial and cytotoxicity. Some of new derivatives showed an
in-vitro antimicrobial activity against B. subtilis, E. coli better
than that of norfloxacin and cytotoxicity against Vero cells
better than that of tamoxifen. Among the compounds re-
ported here in, compounds (12c, 12d, 12g and 12h) is arguably
the most potent, our present study makes it an interesting
compound when compared to the current therapeutic agents
and are considered the candidates to investigate further for
the same.
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